Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.64 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556347 | 0.94 | HDAC1 (0.67) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL1416823 | 0.93 | HDAC1 (0.70) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL5612077 | 0.90 | DRD2 (0.64) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL726223 | 0.88 | GAA (0.63) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL8779817 | 0.88 | HDAC1 (0.79) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL9491686 | 0.88 | NPC1 (0.75) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL7269223 | 0.87 | MAPK1 (0.56) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL9489804 | 0.86 | HDAC1 (0.82) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL9188890 | 0.86 | HDAC1 (0.82) | NPC1RAB9AHDAC1HDAC2HDAC8 | |
| SCHEMBL20734829 | 0.86 | HDAC1 (0.82) | NPC1RAB9AHDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273332-B2 | Method for production of L-amino acid | KANEKA CORPORATION (JP) | 2016-03-01 | — | — | US | claimed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | claimed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | claimed |
| CN-1071751-C | Reversible protease inhibitors | ARRIS PHARM CORP (US) | 2001-09-26 | — | — | CN | claimed |
| CN-1265672-A | Sulphonylated dipeptide Compounds capable of inhibiting leukocyte adhesion mediated by VLA-4 | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | claimed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| US-6030946-A | FUNCTIONS REVERSIBLY, RESULTING IN TIGHT BINDING (LOW DISSOCIATION CONSTANTS) BETWEEN INHIBITOR AND TARGET ENZYME; USED TO TREAT VARIETY OF DISEAES, INCLUDING ARTHRITIS, MUSCULAR DYSTROPHY, INFLAMMATION, TUMOR INVASION, MALERIA | AXYS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | claimed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | claimed |
| CN-1192219-A | Reversible cysteine protease inhibitors | ARRIS PHARM CORP (US) | 1998-09-02 | — | — | CN | claimed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | claimed |
| CN-1184472-A | Reversible protease inhibitors | ARRIS PHARM CORP (US) | 1998-06-10 | — | — | CN | claimed |
| EP-0832099-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0817778-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996040737-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | claimed |
| EP-0548664-B1 | 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives | HOFFMANN LA ROCHE (CH) | 1995-05-31 | — | — | EP | claimed |
| US-5318966-A | Administering the enzyme inhibitor for treating alzheimer's disease, learning enhancement, brain disorders | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | claimed |
| US-5318967-A | Cognition activators for alzheimer's disease, learning enhancement | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | claimed |
| EP-0548664-A1 | 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-30 | — | — | EP | claimed |
| US-4315855-A | Monoazo disperse dyes containing a nitrophenyl group and a homophthalimide group | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | NPC1 3250/4885RAB9A 2770/4885HDAC1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.